GlassScriptPhysician profile
Tracy B Stokes
NPI 1528517802
$1,369.09
in general payments reported to CMS, 2019-2025
25 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $412 · 2023: $268 · 2024: $275 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.44 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $227.15 | 2021-2025 | Keytruda |
| Myriad Genetic Laboratories, INC. | $182.60 | 2021-2024 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $134.57 | 2022-2024 | Lynparza, Enhertu, Calquence |
| Glaxosmithkline, LLC. | $133.48 | 2022-2023 | Shingrix |
| Gilead Sciences, INC. | $84.99 | 2025 | Trodelvy |
| Eisai INC. | $82.10 | 2021-2024 | |
| Caris Mpi, INC. | $80.16 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $63.22 | 2023-2024 | Enhertu, Injectafer |
| Jazz Pharmaceuticals INC. | $52.56 | 2022-2024 | |
| Janssen Biotech, INC. | $43.54 | 2022 | |
| Incyte Corporation | $31.01 | 2022 | |
| Seagen INC. | $29.71 | 2022 | |
| Clovis Oncology, INC. | $28.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.10 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.99 | 2023 | Gilotrif |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $18.58 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.58 | 2023 | Ninlaro |
| Adc Therapeutics America, INC. | $17.45 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.77 | 2023 | Libtayo |
| Emd Serono, INC. | $16.35 | 2023 | Tepmetko |
| Bayer Healthcare Pharmaceuticals INC. | $15.88 | 2022 | |
| Beigene USA, INC. | $15.88 | 2022 | |
| Lilly USA, LLC | $15.02 | 2023 | Retevmo, Jaypirca, Verzenio |
| Mirati Therapeutics, INC. | $12.74 | 2023 | Krazati |
| Puma Biotechnology, INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.